W
WAVEMAN · COMPANY
ENGN · Engene Therapeutics Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

ENGN

enGene Therapeutics Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001980845
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
40
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
40 funds added or opened last quarter
below 59% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
2.6% of shares outstanding short · 2.5 days to cover · settled 2026-07-31
below 59% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
40 funds added or opened positions in the latest 13F quarter, of 70 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -62.1%
-62.1%12M
-70%+5%+79%+154%2025-092025-102025-122026-032026-052026-072026-09
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 40 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for enGene Therapeutics Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Forbion Growth Management B.V.
—
BUY
2024-10-30
561,797.0
$5.0M
Forbion Growth Opportunities Fund I Cooperatief U.A.
—
BUY
2024-10-08
800.0
$5.3K
Forbion Growth Opportunities Fund I Cooperatief U.A.
—
BUY
2024-10-07
11,844.0
$77.6K
Forbion Growth Opportunities Fund I Cooperatief U.A.
—
BUY
2024-10-04
5,997.0
$39.2K
Forbion Growth Opportunities Fund I Cooperatief U.A.
—
BUY
2024-10-03
5,769.0
$37.4K
18 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 13 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FCPM III SERVICES B.V.
12,510,709.0 sh
$17.5M
BML Capital Management, LLC
6,669,908.0 sh
$11.5M
Siren, L.L.C.
6,256,662.0 sh
$10.8M
PERCEPTIVE ADVISORS LLC
4,822,169.0 sh
$8.3M
AMERIPRISE FINANCIAL INC
2,675,876.0 sh
$4.6M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Virtus Biotech Clinical Trials Etf
$237.2K POSITION · AS OF 2026-04-30
0.6%
NORTH SQUARE KENNEDY MICROCAP FUND
$114.0K POSITION · AS OF 2026-02-28
0.4%
Franklin Biotechnology Discovery Fund
$3.5M POSITION · AS OF 2026-04-30
0.3%
Avantis U.S. Small Cap Equity Fund
$59.7K POSITION · AS OF 2026-02-28
0.0%
Select Biotechnology Portfolio
$2.3M POSITION · AS OF 2026-02-28
0.0%
Small Cap Core Fund
$60.9K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-102024-102023-102022-10
OPERATING INCOME$-123.2M$-62.3M$-26.1M$-19.4M
NET INCOME$-117.3M$-55.1M$-99.9M$-24.5M
EPS (DILUTED)2.291.46151.2244.30
OPERATING CASH FLOW$-99.2M$-48.3M$-24.7M$-17.6M
CASH$50.2M$173.0M$81.5M$20.4M
DIVIDENDS PAID——$0—
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →